DOI:
10.1055/s-00034914
Osteologie
LinksClose Window
References
Insogna KL, Briot K, Imel EA. et al.
A randomized, double-blind, Placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an Anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis.
J Bone Miner Res 2018;
33 (08) : 1383-1393
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.